LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MBAI
Check-Cap Ltd. Ordinary Share
There isn't enough reported data to score MBAI yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MBAI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
MBAI's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MBAI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 0.5x | $2.09 | — |
| Cheap | 0.7x | $3.31 | +58% |
| Fair | 2.3x | $10.69 | +412% |
| Expensive | 38x | $177 | +8350% |
Historical ranges are pointers, not guarantees.
MBAI has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MBAI Forward outlook
There aren't enough analyst estimates for MBAI to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MBAI in the latest year-over-year earnings comparison.
MBAI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2021 | -$4.20 | -106% |
| Q4 2020 | -$42.00 | -1100% |
| Q2 2020 | $70.00 | +2400% |
| Q4 2019 | $4.20 | +$126.00 |
MBAI's earnings per share have fallen from their peak: $4.62 over the past year, against $1,780.80 in late 2015.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
MBAI Quarterly Revenue
MBAI and LLY do not have enough comparable growth data to identify a winner.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
MBAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2023 | -$7.1M | +$1.4M |
| Q2 2023 | -$9.9M | +$762K |
| Q4 2022 | -$8.5M | +$727K |
| Q2 2022 | -$10.7M | -$2.7M |
| Q4 2021 | -$9.3M | -$2.3M |
| Q2 2021 | -$8M | -$1.5M |
| Q4 2020 | -$7M | -$366K |
| Q2 2020 | -$6.5M | -$116K |
MBAI has burned cash in almost every quarter: −$36M over the past year, against −$31M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MBAI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MBAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.5% | +54.5K shares |
| 1 year | +6.6% | +54.8K shares |
| 3 years | +4447% | +871K shares |
MBAI has 890,318 diluted shares, up 6.6% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MBAI Net Leverage
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MBAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.6 | Oversold |
| Stochastic | 5.4 | Oversold |
MBAI's weekly RSI is 30 (oversold) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MBAI PE vs Healthcare Sector
| Metric | MBAI | Sector median | Relative |
|---|---|---|---|
| PE | 0.5x | 26x | 98% below |
| PE % | 1 | 29 | 28 pts below |
MBAI has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MBAI on trend strength, trading above more of its moving averages.
MBAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.79 | 25% below |
| 20 week MA | $5.67 | 63% below |
| 50 week MA | $9.15 | 77% below |
| 100 week MA | $8.30 | 75% below |
| 200 week MA | $12.3 | 83% below |
MBAI is in a downtrend: it's below all five of its weekly moving averages, and 83% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MBAI on returns for 2026, with the stronger performance.
MBAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $245.0 | $54.0 | -78% |
| 2021 | $54.0 | $103.3 | +91% |
| 2022 | $103.3 | $14.8 | -86% |
| 2023 | $14.8 | $14.6 | -1.4% |
| 2024 | $14.6 | $7.70 | -47% |
| 2025 | $7.70 | $11.8 | +53% |
| 2026 YTD | $11.8 | $2.09 | -82% |
MBAI has finished lower in four of the last six years. It's down 82% so far in 2026.